Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tetsuya Hosaka

Showing results (131-140 of 306) with videos related to

Pageof 31
Sort By:
Digestive Diseases and Sciences|September 9, 2017
Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular CarcinomaKenji Ikeda, Yusuke Kawamura, Masahiro Kobayashi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|August 3, 2019
Long-term outcome of hepatocellular carcinoma occurrence, esophageal varices exacerbation, and mortality in hepatitis C virus-related liver cirrhosis after interferon-based therapyNobuhiko Ogasawara, Satoshi Saitoh, Norio Akuta, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 22, 2017
Predictors of pruritus in patients with chronic liver disease and usefulness of nalfurafine hydrochlorideNorio Akuta, Hiromitsu Kumada, Shunichiro Fujiyama, et al.
Journal of Medical Virology|January 13, 2017
Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimensNorio Akuta, Hitomi Sezaki, Fumitaka Suzuki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 9, 2014
Effectiveness and safety of reduced-dose telaprevir-based triple therapy in chronic hepatitis C patientsHitomi Sezaki, Fumitaka Suzuki, Tetsuya Hosaka, et al.
Intervirology|October 6, 2012
Efficacy and anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus-related compensated cirrhosisNorio Akuta, Fumitaka Suzuki, Yuya Seko, et al.
Hepatology (Baltimore, Md.)|September 20, 2012
Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis CYasuji Arase, Mariko Kobayashi, Fumitaka Suzuki, et al.
Journal of Medical Virology|August 30, 2012
Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapyNorio Akuta, Fumitaka Suzuki, Yuya Seko, et al.
Journal of Gastroenterology|February 25, 2012
Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in JapanFumitaka Suzuki, Yasuji Arase, Yoshiyuki Suzuki, et al.
Internal Medicine (Tokyo, Japan)|September 20, 2019
Predictors of Insulin Secretion in Japanese Patients with Histopathologically-confirmed Non-alcoholic Fatty Liver DiseaseNorio Akuta, Yusuke Kawamura, Shunichiro Fujiyama, et al.
Pageof 31

Showing results (131-140 of 306) with videos related to

Sort By:
Pageof 31
Digestive Diseases and Sciences|September 9, 2017
Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular CarcinomaKenji Ikeda, Yusuke Kawamura, Masahiro Kobayashi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|August 3, 2019
Long-term outcome of hepatocellular carcinoma occurrence, esophageal varices exacerbation, and mortality in hepatitis C virus-related liver cirrhosis after interferon-based therapyNobuhiko Ogasawara, Satoshi Saitoh, Norio Akuta, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 22, 2017
Predictors of pruritus in patients with chronic liver disease and usefulness of nalfurafine hydrochlorideNorio Akuta, Hiromitsu Kumada, Shunichiro Fujiyama, et al.
Journal of Medical Virology|January 13, 2017
Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimensNorio Akuta, Hitomi Sezaki, Fumitaka Suzuki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 9, 2014
Effectiveness and safety of reduced-dose telaprevir-based triple therapy in chronic hepatitis C patientsHitomi Sezaki, Fumitaka Suzuki, Tetsuya Hosaka, et al.
Intervirology|October 6, 2012
Efficacy and anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus-related compensated cirrhosisNorio Akuta, Fumitaka Suzuki, Yuya Seko, et al.
Hepatology (Baltimore, Md.)|September 20, 2012
Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis CYasuji Arase, Mariko Kobayashi, Fumitaka Suzuki, et al.
Journal of Medical Virology|August 30, 2012
Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapyNorio Akuta, Fumitaka Suzuki, Yuya Seko, et al.
Journal of Gastroenterology|February 25, 2012
Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in JapanFumitaka Suzuki, Yasuji Arase, Yoshiyuki Suzuki, et al.
Internal Medicine (Tokyo, Japan)|September 20, 2019
Predictors of Insulin Secretion in Japanese Patients with Histopathologically-confirmed Non-alcoholic Fatty Liver DiseaseNorio Akuta, Yusuke Kawamura, Shunichiro Fujiyama, et al.
Pageof 31